These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 9432376

  • 1. Electron microscopic analysis of Mycobacterium avium complex isolates exposed to ciprofloxacin, rifabutin, ethambutol and clarithromycin.
    Reisner BS, Woods GL, Popov VL.
    Int J Tuberc Lung Dis; 1997 Jun; 1(3):270-5. PubMed ID: 9432376
    [Abstract] [Full Text] [Related]

  • 2. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex.
    Gordin FM, Sullam PM, Shafran SD, Cohn DL, Wynne B, Paxton L, Perry K, Horsburgh CR.
    Clin Infect Dis; 1999 May; 28(5):1080-5. PubMed ID: 10452638
    [Abstract] [Full Text] [Related]

  • 3. Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages.
    Pellegrin I, Maugein J, Lapeyre C, Barbeau P, Leng B, Pellegrin JL.
    J Antimicrob Chemother; 1996 Mar; 37(3):501-10. PubMed ID: 9182107
    [Abstract] [Full Text] [Related]

  • 4. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
    Suzuki K, Tsuyuguchi K, Matsumoto H, Yamamoto T, Hashimoto T, Tanaka E, Amitani R, Kuze F.
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):460-7. PubMed ID: 9441102
    [Abstract] [Full Text] [Related]

  • 5. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
    Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Aralar P, Wu M, Young LS.
    Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
    [Abstract] [Full Text] [Related]

  • 6. Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group.
    Dubé MP, Torriani FJ, See D, Havlir DV, Kemper CA, Leedom JM, Tilles JG, McCutchan JA, Sattler FR.
    Clin Infect Dis; 1999 Jan; 28(1):136-8. PubMed ID: 10028084
    [Abstract] [Full Text] [Related]

  • 7. Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study Group.
    Shafran SD, Talbot JA, Chomyc S, Davison E, Singer J, Phillips P, Salit I, Walmsley SL, Fong IW, Gill MJ, Rachlis AR, Lalonde RG.
    Clin Infect Dis; 1998 Dec; 27(6):1401-5. PubMed ID: 9868650
    [Abstract] [Full Text] [Related]

  • 8. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
    Cho EH, Huh HJ, Song DJ, Moon SM, Lee SH, Shin SY, Kim CK, Ki CS, Koh WJ, Lee NY.
    J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
    [Abstract] [Full Text] [Related]

  • 9. [Intra-macrophagic activity of antibiotics combinations against Mycobacterium marinum].
    Gevaudan MJ, Bollet C, Mallet MN, de Micco P.
    Pathol Biol (Paris); 1991 May; 39(5):436-41. PubMed ID: 1652732
    [Abstract] [Full Text] [Related]

  • 10. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team.
    Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, Korvick JA, Heifets L, Child CC, Lederman MM, Reichman RC, Powderly WG, Notario GF, Wynne BA, Hafner R.
    J Infect Dis; 2000 Apr; 181(4):1289-97. PubMed ID: 10762562
    [Abstract] [Full Text] [Related]

  • 11. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to various drugs].
    Tomioka H, Sato K, Saito H.
    Kekkaku; 1991 Jul; 66(7):489-92. PubMed ID: 1890791
    [Abstract] [Full Text] [Related]

  • 12. Difference in drug susceptibility distribution and clinical characteristics between Mycobacterium avium and Mycobacterium intracellulare lung diseases in Shanghai, China.
    Wang W, Yang J, Wu X, Wan B, Wang H, Yu F, Guo Y.
    J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
    [Abstract] [Full Text] [Related]

  • 13. Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex.
    Ellis LC, Benson CA, Koenig GI, Trenholme GM.
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2803-6. PubMed ID: 8593025
    [Abstract] [Full Text] [Related]

  • 14. [Resistance testing of M. avium-intracellulare and M. tuberculosis of AIDS patients with new drugs and drug combinations].
    Mauch H, Reichert B, Ruf B, Brehmer W.
    Pneumologie; 1990 Feb; 44 Suppl 1():504-6. PubMed ID: 2114636
    [Abstract] [Full Text] [Related]

  • 15. Comparison of clarithromycin-sensitive and clarithromycin-resistant Mycobacterium avium strains isolated from AIDS patients during therapy regimens including clarithromycin.
    Matsiota-Bernard P, Zinzendorf N, Onody C, Guenounou M.
    J Infect; 2000 Jan; 40(1):49-54. PubMed ID: 10762111
    [Abstract] [Full Text] [Related]

  • 16. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
    Kawata N, Kawahara S, Tada A, Takigawa N, Shibayama T, Soda R, Takahashi K.
    Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
    [Abstract] [Full Text] [Related]

  • 17. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
    van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL.
    Am J Respir Crit Care Med; 2012 Sep 15; 186(6):559-65. PubMed ID: 22744719
    [Abstract] [Full Text] [Related]

  • 18. [Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi].
    Gevaudan MJ, Bollet C, Mallet MN, de Lamballerie X, Sambuc R, de Micco P.
    Pathol Biol (Paris); 1992 May 15; 40(5):443-9. PubMed ID: 1323093
    [Abstract] [Full Text] [Related]

  • 19. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS.
    Cohn DL, Fisher EJ, Peng GT, Hodges JS, Chesnut J, Child CC, Franchino B, Gibert CL, El-Sadr W, Hafner R, Korvick J, Ropka M, Heifets L, Clotfelter J, Munroe D, Horsburgh CR.
    Clin Infect Dis; 1999 Jul 15; 29(1):125-33. PubMed ID: 10433575
    [Abstract] [Full Text] [Related]

  • 20. Rifabutin for MAC questioned.
    Posit Aware; 1995 Jul 15; ():6. PubMed ID: 11362571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.